{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:10:13Z","timestamp":1787170213107,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000555","name":"British Microcirculation Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000555","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014088","name":"AstraZeneca France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014088","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ejca.2020.01.017","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T12:13:35Z","timestamp":1583496815000},"page":"117-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management\u00a0and outcome"],"prefix":"10.1016","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-316X","authenticated-orcid":false,"given":"Emeline","family":"Colomba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Marret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Baciarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernelle","family":"Lavaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Carton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9rome","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Huillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Culine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.01.017_bib1","article-title":"Management of Patients With Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019","volume":"2020","author":"Gillessen","year":"2020","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ejca.2020.01.017_bib2","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","article-title":"Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Parker","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2020.01.017_bib3","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","article-title":"Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017","volume":"73","author":"Gillessen","year":"2018","journal-title":"Eur Urol"},{"issue":"21","key":"10.1016\/j.ejca.2020.01.017_bib4","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2020.01.017_bib5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2020.01.017_bib6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2020.01.017_bib7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2020.01.017_bib8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2020.01.017_bib9","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"Abiraterone in \u201chigh-\u201d and \u201clow-risk\u201d metastatic hormone-sensitive prostate cancer","volume":"76","author":"Hoyle","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ejca.2020.01.017_bib10","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"5\u20136","key":"10.1016\/j.ejca.2020.01.017_bib11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0960-0760(94)90131-7","article-title":"Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase\/C17-20 lyase)","volume":"50","author":"Barrie","year":"1994","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"10.1016\/j.ejca.2020.01.017_bib12","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0960-0760(03)00070-0","article-title":"Effects of novel 17alpha-hydroxylase\/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in\u00a0vitro and in\u00a0vivo","volume":"84","author":"Haidar","year":"2003","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"12","key":"10.1016\/j.ejca.2020.01.017_bib13","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1158\/1078-0432.CCR-10-2815","article-title":"Targeting continued androgen receptor signaling in prostate cancer","volume":"17","author":"Massard","year":"2011","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"27","key":"10.1016\/j.ejca.2020.01.017_bib14","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2011.35.2005","article-title":"Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically","volume":"29","author":"Ryan","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2020.01.017_bib15","unstructured":"A phase III of ADT + docetaxel +\/- local RT +\/- abiraterone acetate in metastatic hormone-na\u00efve prostate cancer - full text view - ClinicalTrials.gov [internet]. [cited 2018 nov 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01957436."},{"issue":"6","key":"10.1016\/j.ejca.2020.01.017_bib16","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s00280-012-1865-3","article-title":"Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men","volume":"69","author":"Acharya","year":"2012","journal-title":"Canc Chemother Pharmacol"},{"issue":"9","key":"10.1016\/j.ejca.2020.01.017_bib17","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1200\/JCO.2009.25.9259","article-title":"Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer","volume":"28","author":"Danila","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2020.01.017_bib18","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","article-title":"Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy","volume":"28","author":"Ryan","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"28","key":"10.1016\/j.ejca.2020.01.017_bib19","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2020.01.017_bib20","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.01.017_bib21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2016.02.013","article-title":"Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: a meta-analysis of published trials","volume":"101","author":"Roviello","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2020.01.017_bib22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12894-016-0132-z","article-title":"Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience","volume":"16","author":"Poon","year":"2016","journal-title":"BMC Urol"},{"issue":"5","key":"10.1016\/j.ejca.2020.01.017_bib23","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bju.12857","article-title":"Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme","volume":"115","author":"Caffo","year":"2015","journal-title":"BJU Int"},{"issue":"11","key":"10.1016\/j.ejca.2020.01.017_bib24","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S1470-2045(14)70417-6","article-title":"Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial","volume":"15","author":"Sternberg","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2020.01.017_bib25","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.juro.2015.07.004","article-title":"Efficacy and safety of abiraterone acetate in elderly (75 Years or older) chemotherapy na\u00efve patients with metastatic castration resistant prostate cancer","volume":"194","author":"Smith","year":"2015","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ejca.2020.01.017_bib26","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1097\/MJT.0000000000000597","article-title":"Abiraterone-associated fulminant liver failure","volume":"25","author":"Singh","year":"2018","journal-title":"Am J Therapeut"},{"issue":"9","key":"10.1016\/j.ejca.2020.01.017_bib27","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1634\/theoncologist.2013-0092","volume":"18","author":"Gravanis","year":"2013","journal-title":"Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2020.01.017_bib28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1432-1033.1993.tb18412.x","article-title":"Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control","volume":"218","author":"Hashimoto","year":"1993","journal-title":"Eur J Biochem"},{"issue":"5","key":"10.1016\/j.ejca.2020.01.017_bib29","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0026-895X(25)09136-9","article-title":"Human liver dehydroepiandrosterone sulfotransferase: molecular cloning and expression of cDNA","volume":"41","author":"Otterness","year":"1992","journal-title":"Mol Pharmacol"},{"issue":"3","key":"10.1016\/j.ejca.2020.01.017_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1067\/mcp.2002.121829","article-title":"Changes in plasma protein binding have little clinical relevance","volume":"71","author":"Benet","year":"2002","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.ejca.2020.01.017_bib31","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/jcph.253","article-title":"Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment","volume":"54","author":"Marbury","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.ejca.2020.01.017_bib32","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1124\/dmd.116.070672","article-title":"In\u00a0vitro and in\u00a0vivo drug-drug interaction studies to assess the effect of abiraterone acetate, abiraterone, and metabolites of abiraterone on CYP2C8 activity","volume":"44","author":"Monbaliu","year":"2016","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"10.1016\/j.ejca.2020.01.017_bib33","unstructured":"ZYTIGA-pi.pdf [Internet]. [cited 2019 May 27]. Available from: http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/ZYTIGA-pi.pdf."},{"issue":"4","key":"10.1016\/j.ejca.2020.01.017_bib34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/00498254.2012.721022","article-title":"A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects","volume":"43","author":"Acharya","year":"2013","journal-title":"Xenobiotica Fate Foreign Compd Biol Syst"},{"key":"10.1016\/j.ejca.2020.01.017_bib35","series-title":"LiverTox: clinical and research information on drug-induced liver injury","article-title":"Abiraterone","year":"2012"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920300320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920300320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:27:08Z","timestamp":1760732828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920300320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":35,"alternative-id":["S0959804920300320"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.01.017","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management\u00a0and outcome","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}